Freedom Meditech (San Diego), a designer of a non-invasive ocular glucose measurement technology for diabetes, reported the opening of new R&D operations in Ohio. The new R&D operation targets a product development services agreement with Magnet (Cleveland) and existing engineering and FDA clinical trial expertise and resources available in Ohio.

Freedom Meditech said that the agreement with Magnet provides it access to high-end optical engineering equipment for upcoming in vivo efficacy studies. Magnet will also provide business growth and product engineering services. Financial terms were not disclosed. Freedom Meditech's current engineering and corporate operations will remain in California.

“We are greatly impressed with the facilities and track record of success in medical product development in Ohio,” said Craig Misrach, president/CEO of Freedom Meditech.